Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [8]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-0369-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD36 Monoclonal Antibody (eBioNL07 (NL07)), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The monoclonal antibody eBioNL07 recognizes human CD36, which is a member of the class B scavenger receptor family. CD36 was originally identified as a platelet-membrane glycoprotein also called glycoprotein IV and a receptor for thrombospondin-1 (TSP-1) and extracellular matrix proteins. Binding to TSP-1 is in the CLESH (CD36 LIMP-II Emp sequence homology) domain of CD36. CD36 expression is broad and includes microvascular (but not large vessel) endothelium, adipocytes, skeletal muscle, dendritic cells, epithelia of the retina, breast, and intestine, smooth muscle cells, and hematopoietic cells, including erythroid precursors, platelets, monocytes/macrophages, DCs and megakaryocytes. Expression on platelets is absent on Nak^a negative donors. Unlike other scavenger receptor, CD36 binds LDL that has been exposed to "minimally" oxidizing conditions. CD36 is also a fatty acid translocase (FAT) necessary for the transport of long-chain fatty acids (LCFAs) and therefore may play a role in atherosclerosis. Applications Reported: This eBioNL07 (NL07) antibody has been reported for use in flow cytometric analysis. Applications Tested: This eBioNL07 (NL07) antibody has been tested by flow cytometric analysis of human peripheral blood cells. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgM
- Antibody clone number
- eBioNL07 (NL07)
- Vial size
- 25 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references Genome-Wide Transcriptional Regulation of the Long Non-coding RNA Steroid Receptor RNA Activator in Human Erythroblasts.
Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations.
IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis.
Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.
Platelet activation and inhibition of malarial cytoadherence by the anti-CD36 IgM monoclonal antibody NL07.
Sawaengdee W, Cui K, Zhao K, Hongeng S, Fucharoen S, Wongtrakoongate P
Frontiers in genetics 2020;11:850
Frontiers in genetics 2020;11:850
Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations.
Philippeos C, Telerman SB, Oulès B, Pisco AO, Shaw TJ, Elgueta R, Lombardi G, Driskell RR, Soldin M, Lynch MD, Watt FM
The Journal of investigative dermatology 2018 Apr;138(4):811-825
The Journal of investigative dermatology 2018 Apr;138(4):811-825
IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis.
Xia F, Li R, Wang C, Yang S, Tian L, Dong H, Pei C, He S, Jiang P, Cheng H, Fang S, Li H, Xu H
Scientific reports 2013;3:1867
Scientific reports 2013;3:1867
Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.
Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I
Oncogene 2013 May 2;32(18):2249-60, 2260.e1-21
Oncogene 2013 May 2;32(18):2249-60, 2260.e1-21
Platelet activation and inhibition of malarial cytoadherence by the anti-CD36 IgM monoclonal antibody NL07.
Alessio M, Greco NJ, Primo L, Ghigo D, Bosia A, Tandon NN, Ockenhouse CF, Jamieson GA, Malavasi F
Blood 1993 Dec 15;82(12):3637-47
Blood 1993 Dec 15;82(12):3637-47
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with 0.25 µg of Mouse IgM Isotype Control Purified (Product # 14-4752-82) (open histogram) or 0.25 µg of Anti-Human CD36 Purified (filled histogram) followed by Anti-Mouse IgM PE (Product # 12-5890-82). Cells in the monocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 (A-E) Comparison of sarcomas and reprogrammed-sarcomas in terms of achieving terminal differentiation as measured by acquisition of the terminal phenotype (both bone via Alizarin Red S staining for calcium deposition and fat via Oil-Red-O staining for lipid accumulation) AND cessation of proliferation via loss of Ki67. (F) MSCs differentiated as controls into bone and fat. (Oil-Red-O images are magnified 10-fold to accentuate lipid formation associated with each cell). Scale bars=10um.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 (A) Morphological comparison of sarcomas, reprogrammed sarcomas, and reprogrammed sarcomas at days 7, 14, 21 and 28 of an erythroid differentiation protocol. Scale bars=10uM. (B) Individual cells on the verge of enucleation from day 28 erythroid differentiation cultures. Scale bars=5uM. The original magnification for all panels in A were x200; and x1000 for B. (C) Percentage of cells from HOS, SW872, SKNEP, Rep-HOS, Rep-SW872, and Rep-SKNEP cultures undergoing erythroid differentiation expressing CD71, CD235a (GPA), CD36, and CD34. Error bars=standard deviation. (D) CD71 and CD235(GPA) immunofluorescence in reprogrammed SW872 cells after 14 and 28 days of erythroid differentiation. green circle=CD235a+/DAPI+; blue circle=CD235-/DAPI+; yellow circle=CD235a+/DAPI-. Scale bars=10um.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 (A) Myc RT-PCR in parental and reprogrammed sarcoma cells following three weeks in either maintenance (control), adipogenic (fat) or osteogenic (bone) differentiation medium. Chromatin immunoprecipitation of the myc promoter using anti-H3K4triMe (B) or anti-HEK27triMe (C) antibodies in either maintenance (control), adipogenic (fat) or osteogenic (bone) differentiation medium. (D) DNA-promoter methylation analysis showing all statistically differentially methylated promoters (T-Test p
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 IRGM1 controls CD36 internalization by regulating actin polymerization. BMMPhi from either Irgm1 +/+ or Irgm1 -/- mice was labeled with CD36 cross-linking antibody. Then, they were either left in 37degC to cross-link CD36 or on ice. Cells were then washed by cold acid wash buffer to deplete surface CD36. Confocal microscope and flow cytometry were used to detect and quantify CD36 internalization respectively. (a and b n = 8/group, p = 0.004). F-actin polymerization was detected by phalloidin-FITC in BMMPhi from either Irgm1 +/+ or Irgm1 -/- mice with or without oxLDL. The fluorescence was measured by confocal microscope and quantified by flow cytometry (c and d, n = 3, p = 0.02). Data are represented as mean +- SEM.